Comparison of HCV-positive and HCV-negative patients with splenic MZL
. | Not available for assessment . | HCV- patients, no. (%) . | HCV+ patients, no. (%) . | P . |
|---|---|---|---|---|
| Total | 0 | 206 | 49 | |
| Men/women | 0 | 110/96 | 16/33 | .01 |
| Age older than 60 y | 0 | 132 (64) | 28 (57) | NS |
| Ann Arbor stage | 0 | NS | ||
| I-II | 6 (3) | 0 | ||
| III-IV | 200 (97) | 49 (100) | ||
| Splenomegaly | 0 | 193 (94) | 48 (98) | NS |
| Bone marrow involvement | 0 | 196 (95) | 45 (92) | NS |
| More than 1 extranodal site | 0 | 32 (16) | 6 (12) | NS |
| Nodal disease | 0 | 84 (41) | 28 (57) | .05 |
| Locoregional lymph nodes | 0 | 16 (8) | 4 (8) | NS |
| Abdominal nonlocoregional lymph nodes | 0 | 46 (22) | 21 (43) | .006 |
| Liver involvement | 0 | 34 (17) | 9 (18) | NS |
| ECOG status 2 or greater | 15 | 18 (9) | 4 (8) | NS |
| B symptoms | 0 | 43 (21) | 2 (4) | .003 |
| Leukemic disease | 6 | 126 (62) | 24 (52) | NS |
| Leukocyte count less than 3500/μL | 3 | 32 (16) | 10 (21) | NS |
| Presence of villous lymphocytes | 0 | 44 (21) | 3 (6) | .01 |
| Hemoglobin level less than 12 g/dL | 4 | 92 (45) | 25 (53) | NS |
| Platelet count less than 100 000/μL | 5 | 50 (25) | 12 (25) | NS |
| LDH level higher than normal | 24 | 50 (26) | 12 (30) | NS |
| β2-microglobulin level higher than normal | 106 | 83 (67) | 20 (80) | NS |
| Serum monoclonal component | 32 | 35 (19) | 18 (40) | .005 |
| Albumin level less than 3.5 g/dL | 48 | 26 (16) | 5 (12) | NS |
| Cryoglobulins | 135 | 1 (1) | 10 (40) | <.001 |
| HBsAg-positivity | 20 | 8 (4) | 3 (7) | NS |
. | Not available for assessment . | HCV- patients, no. (%) . | HCV+ patients, no. (%) . | P . |
|---|---|---|---|---|
| Total | 0 | 206 | 49 | |
| Men/women | 0 | 110/96 | 16/33 | .01 |
| Age older than 60 y | 0 | 132 (64) | 28 (57) | NS |
| Ann Arbor stage | 0 | NS | ||
| I-II | 6 (3) | 0 | ||
| III-IV | 200 (97) | 49 (100) | ||
| Splenomegaly | 0 | 193 (94) | 48 (98) | NS |
| Bone marrow involvement | 0 | 196 (95) | 45 (92) | NS |
| More than 1 extranodal site | 0 | 32 (16) | 6 (12) | NS |
| Nodal disease | 0 | 84 (41) | 28 (57) | .05 |
| Locoregional lymph nodes | 0 | 16 (8) | 4 (8) | NS |
| Abdominal nonlocoregional lymph nodes | 0 | 46 (22) | 21 (43) | .006 |
| Liver involvement | 0 | 34 (17) | 9 (18) | NS |
| ECOG status 2 or greater | 15 | 18 (9) | 4 (8) | NS |
| B symptoms | 0 | 43 (21) | 2 (4) | .003 |
| Leukemic disease | 6 | 126 (62) | 24 (52) | NS |
| Leukocyte count less than 3500/μL | 3 | 32 (16) | 10 (21) | NS |
| Presence of villous lymphocytes | 0 | 44 (21) | 3 (6) | .01 |
| Hemoglobin level less than 12 g/dL | 4 | 92 (45) | 25 (53) | NS |
| Platelet count less than 100 000/μL | 5 | 50 (25) | 12 (25) | NS |
| LDH level higher than normal | 24 | 50 (26) | 12 (30) | NS |
| β2-microglobulin level higher than normal | 106 | 83 (67) | 20 (80) | NS |
| Serum monoclonal component | 32 | 35 (19) | 18 (40) | .005 |
| Albumin level less than 3.5 g/dL | 48 | 26 (16) | 5 (12) | NS |
| Cryoglobulins | 135 | 1 (1) | 10 (40) | <.001 |
| HBsAg-positivity | 20 | 8 (4) | 3 (7) | NS |
NA indicates not available; NS, not significant.